661 results found
King JA, Desai A, Semple T, et al., 2022, Case-based discussion: neonates on extracorporeal membrane oxygenation for undiagnosed recalcitrant pulmonary hypertension-management challenges, THORAX, ISSN: 0040-6376
Zhang YZ, Nicholson AG, Ly F, et al., 2022, Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave), Publisher: ELSEVIER SCIENCE INC, Pages: S112-S114, ISSN: 1556-0864
Marinescu D-C, Raghu G, Remy-Jardin M, et al., 2022, Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis, CHEST, Vol: 162, Pages: 614-629, ISSN: 0012-3692
Zhang YZ, Sherlock S, Brambilla C, et al., 2022, Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases, Publisher: ELSEVIER SCIENCE INC, Pages: S516-S517, ISSN: 1556-0864
Nicholson AG, Scagliotti G, Tsao MS, et al., 2022, 2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification., J Thorac Oncol, Vol: 17, Pages: e80-e83
Raghu G, Remy-Jardin M, Ryerson CJ, et al., 2022, Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline (vol 202, pg e36, 2020), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 206, Pages: 518-518, ISSN: 1073-449X
Cottin V, Selman M, Inoue Y, et al., 2022, Syndrome of Combined Pulmonary Fibrosis and Emphysema An Official ATS/ERS/JRS/ALAT Research Statement, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 206, Pages: E7-E41, ISSN: 1073-449X
Molyneaux PL, Fahy WA, Byrne AJ, et al., 2022, CYFRA 21-1 predicts progression in IPF: a prospective longitudinal analysis of the PROFILE cohort, American Journal of Respiratory and Critical Care Medicine, Vol: 205, Pages: 1440-1448, ISSN: 1073-449X
OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal condition for which there are a lack of effective biomarkers to guide therapeutic decision making. RATIONALE: To determine the relationship between serum levels of the cytokeratin fragment CYFRA 21-1 and disease progression and mortality in individuals with IPF enrolled in the PROFILE study. METHODS: CYFRA 21-1 was identified by immunohistochemistry in samples of human lung. Concentrations of CYFRA 21-1 were measured using an Elisa-based assay in serum, collected at baseline, 1- and 3-months, from 491 individuals with an incident diagnosis of IPF enrolled in the PROFILE study and from 100 control subjects. Study subjects were followed for a minimum of 3 years. MEASUREMENTS AND MAIN RESULTS: CYFRA 21-1 localises to hyperplastic epithelium in IPF lung. CYFRA 21-1 levels were significantly higher in IPF subjects compared to healthy controls in both discovery (n=132) (control 0.96±0.81 ng/mL versus IPF; 2.34±2.15 ng/mL, p < 0.0001) and validation (n=359) (control; 2.21±1.54 ng/mL and IPF; 4.13±2.77 ng/mL, p<0.0001) cohorts. Baseline levels of CYFRA 21-1 distinguished individuals at risk of 12-month disease progression (C-statistic 0.70 (95% CI 0.61-0.79), p < 0.0001) and were predictive of overall-mortality (HR 1.12 (1.06-1.19) per 1 ng/mL increase in CYFRA 21-1, p=0.0001). Furthermore, 3-month change in levels of CYFRA 21-1 separately predicted 12-month and overall survival in both the discovery and validation cohorts. CONCLUSIONS: CYFRA 21-1, a marker of epithelial damage and turnover, has the potential to be an important prognostic and therapeutic biomarker in individuals with IPF.
Ruffini E, Rami-Porta R, Huang J, et al., 2022, The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 838-851, ISSN: 1556-0864
Roden AC, Ahmad U, Cardillo G, et al., 2022, Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 637-650, ISSN: 1556-0864
Swain SM, Nishino M, Lancaster LH, et al., 2022, Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)- related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management, CANCER TREATMENT REVIEWS, Vol: 106, ISSN: 0305-7372
Raghu G, Remy-Jardin M, Richeldi L, et al., 2022, Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 205, Pages: E18-E47, ISSN: 1073-449X
Sauter JL, Dacic S, Galateau-Salle F, et al., 2022, The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 608-622, ISSN: 1556-0864
Nastase A, Mandal A, Lu SK, et al., 2022, Integrated genomics point to immune vulnerabilities in pleural mesothelioma (vol 11, 19138, 2021), SCIENTIFIC REPORTS, Vol: 12, ISSN: 2045-2322
Tsao M-S, Nicholson AG, Maleszewski JJ, et al., 2022, Reprint of "Introduction to 2021 WHO Classification of Thoracic Tumors", JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 337-340, ISSN: 1556-0864
Nicholson AG, Tsao MS, Beasley MB, et al., 2022, The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 362-387, ISSN: 1556-0864
Popat S, Baas P, Faivre-Finn C, et al., 2022, Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, Vol: 33, Pages: 129-142, ISSN: 0923-7534
Marx A, Chan JKC, Chalabreysse L, et al., 2022, The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: 200-213, ISSN: 1556-0864
Macaluso C, Boccabella C, Kokosi M, et al., 2022, Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis, Respirology, Vol: 27, Pages: 202-208, ISSN: 1323-7799
Background and objectiveA proportion of patients with fibrotic hypersensitivity pneumonitis (fHP) follow a progressive disease course despite immunosuppressive treatment. Little is known about predictors of mortality in fHP. We aimed to investigate the impact of short-term lung function changes in fHP on mortality.MethodsBaseline demographics for 145 consecutive patients with a multi-disciplinary team diagnosis of fHP, as well as baseline and 1-year follow-up of lung function, baseline echocardiographic findings, bronchoalveolar lavage (BAL) cellularity and all-cause mortality were recorded. Changes in forced vital capacity (FVC) ≥ 5% and ≥10%, and diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 10% and ≥15% at 1 year were calculated. Cox proportional hazards analysis was performed to test for associations with mortality.ResultsBaseline lung function severity, age, presence of honeycombing on computed tomography (CT) and echocardiographic pulmonary arterial systolic pressure (PASP) ≥ 40 mm Hg were associated with early mortality, while BAL lymphocytosis was associated with improved survival. A decline in FVC ≥ 5% (hazard ratio [HR]: 3.10, 95% CI: 2.00–4.81, p < 0.001), FVC ≥ 10% (HR: 3.11, 95% CI: 1.94–4.99, p < 0.001), DLCO ≥ 10% (HR: 2.80, 95% CI: 1.78–4.42, p < 0.001) and DLCO ≥ 15% (HR: 2.92, 95% CI: 1.18–4.72, p < 0.001) at 1 year was associated with markedly reduced survival on univariable and multivariable analyses after correcting for demographic variables, disease severity, honeycombing on CT and treatment, as well as BAL lymphocytosis and PASP ≥ 40 mm Hg on echocardiography, in separate models.ConclusionWorsening in FVC and DLCO at 1 year, including a marginal decline in FVC ≥ 5% and DLCO&th
Mackintosh JA, Wells AU, Cottin V, et al., 2021, Interstitial pneumonia with autoimmune features: challenges and controversies, EUROPEAN RESPIRATORY REVIEW, Vol: 30, ISSN: 0905-9180
Tsao M-S, Nicholson AG, Maleszewski JJ, et al., 2021, Introduction to 2021 WHO Classification of Thoracic Tumors, JOURNAL OF THORACIC ONCOLOGY, Vol: 17, Pages: E1-E4, ISSN: 1556-0864
Nicholson AG, Moreira AL, Mino-Kenudson M, et al., 2021, Grading in Lung Adenocarcinoma: Another New Normal, JOURNAL OF THORACIC ONCOLOGY, Vol: 16, Pages: 1601-1604, ISSN: 1556-0864
Nastase A, Mandal A, Lu SK, et al., 2021, Integrated genomics point to immune vulnerabilities in pleural mesothelioma, Scientific Reports, Vol: 11, ISSN: 2045-2322
Pleural mesothelioma is an aggressive malignancy with limited effective therapies. In order to identify therapeutic targets, we integrated SNP genotyping, sequencing and transcriptomics from tumours and low-passage patient-derived cells. Previously unrecognised deletions of SUFU locus (10q24.32), observed in 21% of 118 tumours, resulted in disordered expression of transcripts from Hedgehog pathways and the T-cell synapse including VISTA. Co-deletion of Interferon Type I genes and CDKN2A was present in half of tumours and was a predictor of poor survival. We also found previously unrecognised deletions in RB1 in 26% of cases and show sub-micromolar responses to downstream PLK1, CHEK1 and Aurora Kinase inhibitors in primary mesothelioma cells. Defects in Hippo pathways that included RASSF7 amplification and NF2 or LATS1/2 mutations were present in 50% of tumours and were accompanied by micromolar responses to the YAP1 inhibitor Verteporfin. Our results suggest new therapeutic avenues in mesothelioma and indicate targets and biomarkers for immunotherapy.
Bhatt R, Semple T, Slater O, et al., 2021, Extracorporeal membrane oxygenation: Bridging therapy in paediatric pulmonary Langerhans cell histiocytosis, JOURNAL OF PAEDIATRICS AND CHILD HEALTH, Vol: 58, Pages: 906-908, ISSN: 1034-4810
Lindsay CR, Shaw EC, Moore DA, et al., 2021, Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists, British Journal of Cancer, Vol: 125, Pages: 1210-1216, ISSN: 0007-0920
Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
Ravaglia C, Nicholson AG, 2021, Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype, CURRENT OPINION IN PULMONARY MEDICINE, Vol: 27, Pages: 355-362, ISSN: 1070-5287
Pyae PK, Cama R, Nicholson AG, et al., 2021, Curious case of the unexplained exudative pleural effusion, BMJ CASE REPORTS, Vol: 14
Bui LT, Winters NI, Chung M-I, et al., 2021, Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity, NATURE COMMUNICATIONS, Vol: 12
Willis-Owen S, Domingo Sabugo C, Starren E, et al., 2021, Y disruption, autosomal hypomethylation and poor male lung cancer survival, Scientific Reports, Vol: 11, ISSN: 2045-2322
Lung cancer is the most frequent cause of cancer death worldwide. It affects more men than women, and men generally have worse survival outcomes. We compared gene co-expression networks in affected and unaffected lung tissue from 126 consecutive patients with Stage IA–IV lung cancer undergoing surgery with curative intent. We observed marked degradation of a sex-associated transcription network in tumour tissue. This disturbance, detected in 27.7% of male tumours in the discovery dataset and 27.3% of male tumours in a further 123-sample replication dataset, was coincident with partial losses of the Y chromosome and extensive autosomal DNA hypomethylation. Central to this network was the epigenetic modifier and regulator of sexually dimorphic gene expression, KDM5D. After accounting for prognostic and epidemiological covariates including stage and histology, male patients with tumour KDM5D deficiency showed a significantly increased risk of death (Hazard Ratio [HR] 3.80, 95% CI 1.40–10.3, P = 0.009). KDM5D deficiency was confirmed as a negative prognostic indicator in a further 1100 male lung tumours (HR 1.67, 95% CI 1.4–2.0, P = 1.2 × 10–10). Our findings identify tumour deficiency of KDM5D as a prognostic marker and credible mechanism underlying sex disparity in lung cancer.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.